Tags

Type your tag names separated by a space and hit enter

N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination.
J Nutr Biochem. 2006 Jun; 17(6):379-84.JN

Abstract

The aim of this study was to study the effect of adding polyunsaturated fatty acid (PUFA) n-3 or placebo (containing oleic acid) to a combined statin-fibrate treatment on plasma lipoproteins, lipoperoxidation, glucose homeostasis, total homocysteine (tHcy) and microalbuminuria (MA) in patients with diabetic dyslipidemia (DDL). Twenty-four patients, who did not fulfill the recommended target lipid values with combined hypolipidemic therapy (pravastatin 20 mg+micronized fenofibrate 200 mg daily), were supplemented with 3.6 g PUFA n-3 daily for 3 months or placebo (olive oil) for the next 3 months. The concentrations of plasma lipids, fatty acid (FA) profiles of phosphatidylcholine (PC), cholesteryl esters (CE) and triglycerides (TG), tHcy levels, concentrations of conjugated dienes (CD) in low-density lipoprotein (LDL), and MA were determined in baseline state, after the PUFA n-3 and placebo treatment period. Supplementation with PUFA n-3 led to a significant decrease in plasma tHcy (-29%, P < .01) and TG (-28%, P < .05) levels, as well as to a significant decrease in MA (-24%, P < .05). The decrease in MA correlated significantly with the increase in total PUFA n-3 (r = -.509, P < or = .05) and docosahexaenoic acid (r = -.52, P < .01) in TG. The concentrations of CD in LDL increased significantly (+15%, P < .05). The supplementation with PUFA n-3 to the combined statin-fibrate treatment in patients with DDL decreased the TG and tHcy levels as well as MA. It could lead to decreased risk of atherothrombosis and delay of diabetic nephropathy onset and progression.

Authors+Show Affiliations

Fourth Department of Medicine, First Faculty of Medicine, Charles University, Prague, 128 08 The Czech Republic. mirozem@seznam.csNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16214329

Citation

Zeman, Miroslav, et al. "N-3 Fatty Acid Supplementation Decreases Plasma Homocysteine in Diabetic Dyslipidemia Treated With Statin-fibrate Combination." The Journal of Nutritional Biochemistry, vol. 17, no. 6, 2006, pp. 379-84.
Zeman M, Zák A, Vecka M, et al. N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination. J Nutr Biochem. 2006;17(6):379-84.
Zeman, M., Zák, A., Vecka, M., Tvrzická, E., Písaríková, A., & Stanková, B. (2006). N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination. The Journal of Nutritional Biochemistry, 17(6), 379-84.
Zeman M, et al. N-3 Fatty Acid Supplementation Decreases Plasma Homocysteine in Diabetic Dyslipidemia Treated With Statin-fibrate Combination. J Nutr Biochem. 2006;17(6):379-84. PubMed PMID: 16214329.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination. AU - Zeman,Miroslav, AU - Zák,Ales, AU - Vecka,Marek, AU - Tvrzická,Eva, AU - Písaríková,Alexandra, AU - Stanková,Barbora, Y1 - 2005/09/19/ PY - 2005/02/09/received PY - 2005/08/03/revised PY - 2005/08/12/accepted PY - 2005/10/11/pubmed PY - 2006/7/21/medline PY - 2005/10/11/entrez SP - 379 EP - 84 JF - The Journal of nutritional biochemistry JO - J Nutr Biochem VL - 17 IS - 6 N2 - The aim of this study was to study the effect of adding polyunsaturated fatty acid (PUFA) n-3 or placebo (containing oleic acid) to a combined statin-fibrate treatment on plasma lipoproteins, lipoperoxidation, glucose homeostasis, total homocysteine (tHcy) and microalbuminuria (MA) in patients with diabetic dyslipidemia (DDL). Twenty-four patients, who did not fulfill the recommended target lipid values with combined hypolipidemic therapy (pravastatin 20 mg+micronized fenofibrate 200 mg daily), were supplemented with 3.6 g PUFA n-3 daily for 3 months or placebo (olive oil) for the next 3 months. The concentrations of plasma lipids, fatty acid (FA) profiles of phosphatidylcholine (PC), cholesteryl esters (CE) and triglycerides (TG), tHcy levels, concentrations of conjugated dienes (CD) in low-density lipoprotein (LDL), and MA were determined in baseline state, after the PUFA n-3 and placebo treatment period. Supplementation with PUFA n-3 led to a significant decrease in plasma tHcy (-29%, P < .01) and TG (-28%, P < .05) levels, as well as to a significant decrease in MA (-24%, P < .05). The decrease in MA correlated significantly with the increase in total PUFA n-3 (r = -.509, P < or = .05) and docosahexaenoic acid (r = -.52, P < .01) in TG. The concentrations of CD in LDL increased significantly (+15%, P < .05). The supplementation with PUFA n-3 to the combined statin-fibrate treatment in patients with DDL decreased the TG and tHcy levels as well as MA. It could lead to decreased risk of atherothrombosis and delay of diabetic nephropathy onset and progression. SN - 0955-2863 UR - https://www.unboundmedicine.com/medline/citation/16214329/N_3_fatty_acid_supplementation_decreases_plasma_homocysteine_in_diabetic_dyslipidemia_treated_with_statin_fibrate_combination_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0955-2863(05)00216-0 DB - PRIME DP - Unbound Medicine ER -